(40) found that the degree of change in TL-PSMA (87%) was more consistent with the change in PSA level than SUVmax (74%) in their study to evaluate treatment response of PCa treatment using PET/CT parameters. The gene discussed is FOLH1; the disease is posterior cortical atrophy.